FDA Grants Breakthrough Device Designation to Neola® for Continuous Lung Monitoring in Preterm Infants
核心洞察
Neola Medical AB (搜索) received FDA Breakthrough Device Designation for Neola® (搜索), a non-invasive, continuous lung monitoring device for preterm born babies.
The device aims to support timely detection of potentially life-threatening lung collapse, including pneumothorax (搜索), a severe pulmonary complication in neonatal intensive care.
The designation provides more frequent and interactive FDA communication and prioritized review of regulatory submissions, strengthening the company's U.S. regulatory pathway.
Neola Medical AB (搜索) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (搜索) (FDA) for Neola® (搜索), the company's medical device for non-invasive, continuous lung monitoring in preterm born babies, with the intended use to support timely detection of potentially life-threatening lung collapse. The designation represents a significant regulatory and strategic milestone for Neola Medical and its U.S. regulatory pathway.
"This is an important recognition of the potential of Neola® (搜索) to address a critical unmet need in neonatal intensive care," said Hanna Sjöström, CEO of Neola Medical. "Receiving Breakthrough Device Designation from the FDA is a major milestone for Neola Medical and strengthens our U.S. regulatory pathway. It gives us the opportunity for a more direct and prioritized dialogue with the FDA, which may support a more efficient regulatory process and accelerate our route to market."
A Critical Unmet Need in Neonatal Care
Neola® (搜索) is being developed to continuously monitor the lungs of preterm born babies without invasive procedures. The device's patented technology, developed at Lund University in Sweden, uses near-infrared light measurements in the lungs to detect changes and provide real-time alerts of potentially life-threatening lung collapse.
Pneumothorax (搜索) is a severe pulmonary complication in which air accumulates between the lung and chest wall, potentially causing the lung to collapse. For vulnerable preterm infants receiving care in neonatal intensive care units, earlier identification of such complications may support timely clinical intervention and decision-making. The FDA designation supports Neola Medical's focus on high-value clinical use cases where continuous lung monitoring may provide meaningful clinical benefit, particularly in the detection of life-threatening lung collapse.
Regulatory Pathway and Next Steps
Through the FDA's Breakthrough Devices Program, Neola Medical gains the opportunity for more frequent and interactive communication with the FDA during development, as well as prioritized review of subsequent regulatory submissions. The program is designed to provide patients and healthcare providers with more timely access to medical devices that have the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
Following the designation, Neola Medical will continue its regulatory and clinical preparations in the United States, including further dialogue with the FDA regarding the evidence required to support future market authorization. The Breakthrough Device Designation does not constitute market approval, clearance, or authorization by the FDA, and the company will need to complete further clinical and regulatory requirements before the device can become commercially available in the U.S.
Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). The company's Certified Adviser is FNCA Sweden AB.